Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 157

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 157
---
 stock underlying convertible preferred stock warrants 
     -  
     119  
     60 
  
    Exercise
    of warrants for common stock 
     159,724  
     5,080  
     - 
  
    Common
    stock underlying outstanding options (2024 Plan) 
     74,151  
     2,520  
     25 

     881,026  
     8,246  
     985 

Restricted common stock can be issued to directors, executives or employees
of the Company and are subject to time-based vesting. These potential shares are excluded from the computation of basic loss per share
as these shares are not considered outstanding until vested. No unvested restricted common stock awards were issued or outstanding during
the six months ended June 30, 2025 or the six month period ended June 30, 2024.

NOTE
5 – PROPERTY AND EQUIPMENT

Property
and equipment, net, consisted of the following as of June 30, 2025 and December 31, 2024:

    June 30,  
    December 31, 

    2025  
    2024 

    (Successor)  
    (Successor) 
  
    Laboratory equipment 
    $2,507,839  
    $2,507,839 
  
    Computers 
     38,323  
     38,323 
  
    Furniture 
     8,429  
     8,429 
  
    Total cost 
     2,554,591  
     2,554,591 
  
    Less: accumulated depreciation 
     (2,171,785) 
     (2,026,070)
  
    Property and equipment,
    net 
    $382,806  
    $528,521 

Successor depreciation expense for the three months ended June 30,
2025 and 2024 was $76,294 and $114,304, and for the six months ended June 30, 2025 and for period from February 14, 2024 through June
30, 2024 Successor depreciation expense was $145,715 and $190,591, respectively. Predecessor depreciation expense for the period January
1, 2024 through February 13, 2024 was $37,356.

NOTE
6 – ACCRUED LIAB